Correction: Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway

Mathieu Chocry; Ludovic Leloup; Hervé Kovacic

doi:10.18632/oncotarget.25605

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway

PDF | How to cite

Oncotarget. 2018; 9:26978-26979. https://doi.org/10.18632/oncotarget.25605

Metrics: PDF 1431 views | ?

Mathieu Chocry¹, Ludovic Leloup¹ and Hervé Kovacic¹

¹Aix-Marseille Université, INSERM, CRO2 UMR_S 911, Marseille 13385, France

Published: June 01, 2018

This article has been corrected: The correct figures are given below: The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:103710-103730. DOI: https://doi.org/10.18632/oncotarget.21780.

Figure 2: Implication of Nox1 in oxaliplatin-induced ROS production and cytotoxicity. (D). Transfected cells were also seeded in white 96-well plates to perform lucigenin assays.

Figure 3: Study of calpain expression, activity and implication in oxaliplatin-induced cytotoxicity. (C). The transfected cells were also seeded to perform 72-hour cytotoxicity assays (C). Asteriks indicate a statistical significance with p<0.05.

Figure 7: Implication of p38 in the resistance to oxaliplatin. (B to D). Cytotoxicity assays were performed with HT29-D4, Rox1 and Rox2 treated with oxaliplatin and incubated in the absence (Control) or in the presence of SB203580, a specific inhibitor of p38 (5 μM).

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25605

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Reversion of resistance to oxaliplatin by inhibition of p38 MAPK in colorectal cancer cell lines: involvement of the calpain / Nox1 pathway